China’s Ministry of Commerce announced on Tuesday the inclusion of a major US biotech company on its “unreliable entity list” while stating that the firm’s “discriminatory measures against Chinese enterprises” harmed the legitimate rights and interests of Chinese companies. Leading American genomic sequencing firm Illumina is the first biotech company on Beijing’s list. More than 60 per cent of the world’s genetic sequencing data is generated by Illumina’s machines. After being blacklisted by Beijing, the company’s stock price fell 5 per cent. The ministry’s announcement came as Beijing unveiled retaliatory measures against the United States as the two countries brace for a renewed trade war. China’s Ministry of Finance said it would impose punitive tariffs of 10 to 15 per cent on some US products from February 10. The US has been a world leader in biotechnology. China’s listing of Illumina as an unreliable entity marks a turning point in the life sciences branch of the superpowers’ tech war. The development reflects both China’s biotech advances that move to close the gap with US scientists and firms and Beijing’s push to protect its national security concerns and commercial interests.

Full report : Leading American genomic sequencing firm Illumina says it is evaluating Beijing’s announcement with hope of ‘positive resolution’.